Mei Ri Jing Ji Xin Wen·2026-01-08 23:09Group 1: Acquisition and Strategic Moves - Eli Lilly announced the acquisition of Ventyx Biosciences for $1.2 billion, with a premium of 62%, to enhance its NLRP3 inhibitor pipeline, expected to complete in the first half of 2026 [1] - Bangyao Biotech appointed Xiang Yu as CEO starting January 1, 2026, who brings 17 years of experience in the pharmaceutical and healthcare sectors, aiming to accelerate the commercialization of CGT pipelines [2] Group 2: Market Performance and Product Approvals - Jingfeng Medical's stock surged over 30% on its first day of trading in Hong Kong, reflecting strong market confidence in its surgical robot technology and global strategy [3] - Luye Pharma's innovative drug Ruoxinlin received acceptance for a new indication application in China, targeting generalized anxiety disorder, with a clinical efficacy rate exceeding 80% [4] - Hansoh Pharmaceutical's Amivantamab was approved for a new indication in combination with chemotherapy for advanced non-small cell lung cancer patients with specific EGFR mutations, reinforcing its position in the EGFR-TKI market [5]